| Literature DB >> 28081265 |
Isabelle Bleiziffer1,2, Julian Eikmeier1,2, Gottfried Pohlentz3, Kathryn McAulay4, Guoqing Xia5, Muzaffar Hussain1, Andreas Peschel6,7, Simon Foster4, Georg Peters1,2,8, Christine Heilmann1,2.
Abstract
Most bacterial glycoproteins identified to date are virulence factors of pathogenic bacteria, i.e. adhesins and invasins. However, the impact of protein glycosylation on the major human pathogen Staphylococcus aureus remains incompletely understood. To study protein glycosylation in staphylococci, we analyzed lysostaphin lysates of methicillin-resistant Staphylococcus aureus (MRSA) strains by SDS-PAGE and subsequent periodic acid-Schiff's staining. We detected four (>300, ∼250, ∼165, and ∼120 kDa) and two (>300 and ∼175 kDa) glycosylated surface proteins with strain COL and strain 1061, respectively. The ∼250, ∼165, and ∼175 kDa proteins were identified as plasmin-sensitive protein (Pls) by mass spectrometry. Previously, Pls has been demonstrated to be a virulence factor in a mouse septic arthritis model. The pls gene is encoded by the staphylococcal cassette chromosome (SCC)mec type I in MRSA that also encodes the methicillin resistance-conferring mecA and further genes. In a search for glycosyltransferases, we identified two open reading frames encoded downstream of pls on the SCCmec element, which we termed gtfC and gtfD. Expression and deletion analysis revealed that both gtfC and gtfD mediate glycosylation of Pls. Additionally, the recently reported glycosyltransferases SdgA and SdgB are involved in Pls glycosylation. Glycosylation occurs at serine residues in the Pls SD-repeat region and modifying carbohydrates are N-acetylhexosaminyl residues. Functional characterization revealed that Pls can confer increased biofilm formation, which seems to involve two distinct mechanisms. The first mechanism depends on glycosylation of the SD-repeat region by GtfC/GtfD and probably also involves eDNA, while the second seems to be independent of glycosylation as well as eDNA and may involve the centrally located G5 domains. Other previously known Pls properties are not related to the sugar modifications. In conclusion, Pls is a glycoprotein and Pls glycosyl residues can stimulate biofilm formation. Thus, sugar modifications may represent promising new targets for novel therapeutic or prophylactic measures against life-threatening S. aureus infections.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28081265 PMCID: PMC5230774 DOI: 10.1371/journal.ppat.1006110
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Bacterial strains used in this study.
| Strains and plasmids | Genotype or description | Source |
|---|---|---|
| COL | Clinical MRSA expressing | [ |
| COL | Deficient in | This study |
| 1061 | Clinical MRSA expressing | [ |
| 1061 | Deficient in | [ |
| 1061 | Complemented | [ |
| 1061 | Deletion of SD repeats of Pls (Tcr Cmr) | [ |
| 1061 | Production of Pls with 17 aa of SD repeats (Tcr Cmr) | This study |
| 1061 | Production of Pls with 34 aa of SD repeats (Tcr Cmr) | This study |
| 1061 | Production of Pls with 130 aa of SD repeats (Tcr Cmr) | This study |
| SA113 | ATCC 35556, NCTC 8325 derivative, | [ |
| SA113 (pCU1) | Empty vector control (Cmr) | This study |
| SA113 (pPLS4) | Expression of | This study |
| SA113 | Deficient in | This study |
| SA113 | Deficient in the putative | This study |
| SA113 | Deficient in | This study |
| SA113 | Deficient in | This study |
| SA113 | Empty vector control (Emr Cmr) | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SA113 | Expression of | This study |
| SH1000 | ATCC 35556, NCTC 8325 derivative, | [ |
| SH1000 (pPLS4) | Expression of | This study |
| SH1000 | Deficient in | This study |
| SH1000 | Expression of | This study |
| Newman | NCTC 8178, clinical isolate | [ |
| Newman (pPLS4) | Expression of | This study |
| Newman (pCU1) | Empty vector control (Emr Cmr) | This study |
| Newman (pPlsGtfCDCOL) | Expression of | This study |
| Newman (pPlsGtfΔCΔDCOL) | Expression of | This study |
| Newman (pΔPlsGtfCDCOL) | Expression of Δ | This study |
| NewmanC | Newman (pPlsGtfCDCOL) cured from its plasmid | This study |
| NewmanC (pCU1) | NewmanC transformed with plasmid pCU1 | This study |
| Newman | Deficient in | This study |
| Newman | Expression of | This study |
| Newman | Empty vector control (Emr Cmr) | This study |
| Newman | Expression of | This study |
| Newman | Expression of | This study |
| Newman | Expression of Δ | This study |
| Newman | Newman | This study |
| Newman | Newman | This study |
| Cowan 1 | ATCC 12598, NCTC 8530, isolate from septic arthritis | [ |
| TM300 | Non-pathogenic reference isolate | [ |
| TM300 (pCU1) | Empty vector control (Cmr) | This study |
| TM300 (pPlsGtfCDCOL) | Expression of | This study |
| TM300 (pPlsGtfΔCDCOL) | Expression of | This study |
| TM300 (pPlsGtfCΔDCOL) | Expression of | This study |
| TM300 (pPlsGtfΔCΔDCOL) | Expression of | This study |
| TM300 (pPlsGtfCD1061) | Expression of | This study |
| TM300 (pPlsGtfΔCD1061) | Expression of | This study |
| TM300 (pPlsGtfCΔD1061) | Expression of | This study |
| TM300 (pPlsGtfΔCΔD1061) | Expression of | This study |
| RP62A | Strong biofilm producer | [ |
| XL1-Blue | [ |
aMRSA, methicillin-resistant S. aureus; gtf, glycosyltransferase; bgt, bactoprenol glycosyltransferase, pls, plasmin-sensitive protein; Tcr, tetracycline resistant; Cmr, chloramphenicol resistant; Emr, erythromycin resistant; Kanr, kanamycin resistant.
Fig 1The S. aureus plasmin-sensitive protein Pls is a glycoprotein.
(A) For all samples, left panel are Coomassie-Blue stained gels (10% separation gel) corresponding to PAS staining (right panel) to detect glycosylated proteins. Lane 1, marker proteins; Lane 2, surface proteins from I, S. aureus COL, stationary phase; II, S. aureus COL, exponential phase, III, S. aureus COL surface-associated proteins; IV, S. aureus 1061, stationary phase; V, S. carnosus TM300 stationary phase. The stars indicate the proteins subjected to MS. (B) The 250-kDa, 165-kDa, and 175-kDa proteins were identified as Pls by MS. For each analysis, 10 detected peptides are given with their aa positions (Start, End), observed monoisotopic mass of the respective peptide in the spectrum [Observed (m/z)], experimental mass of the respective peptide calculated from the observed m/z value [Mr (expt)], theoretical mass of the respective peptide based on its sequence [Mr (calc)], difference between the theoretical Mr (calc) and experimental Mr (expt) masses [delta (Da)], number of missed trypsin cleavage sites (Miss) and peptide sequences (Peptide). The dots indicate trypsin cleavage sites. (C) SDS-PAGE (10% separation gel) (left) and corresponding PAS staining (right) of surface proteins from S. aureus 1061 (lane 2), S. aureus 1061pls (lane 3), and S. aureus 1061pls (pPLS4) (lane 4).
Fig 5The SD-repeat region of Pls is glycosylated.
(A) Schematic map of Pls from strain 1061 and its truncated derivatives encoded by the indicated plasmids. SD; SD-repeat region, G5; G5 domains, LPXTG; C-terminal cell-wall anchor motif. (B) SDS-PAGE (7.5% separation gel) (upper panel) and corresponding PAS staining (lower panel) of surface proteins from the strains S. aureus 1061 (lane 2), 1061pls (lane 3), 1061pls (pPLS4) (lane 4), 1061pls (pPLS6) (lane 5), 1061pls (pPLSsub1) (lane 6), 1061pls (pPLSsub2) (lane 7), 1061pls (pPLSsub3) (lane 8). The sizes of the marker proteins (lane 1; kDa) are indicated on the left.
Fig 2The glycosyltransferases SdgA/SdgB are involved in the glycosylation of Pls.
(A) SDS-PAGE (7.5% separation gel) (upper panel) and corresponding PAS staining (lower panel) of surface proteins from S. aureus SA113 (lane 2), SA113 (pPLS4) (lane 3), SA113bgt (pPLS4) (lane 4), SA113gtfA (pPLS4) (lane 5), SA113sdgA/sdgB (pPLS4) (lane 6), and SA113gtfA/sdgA/sdgB (pPLS4) (lane 7). Glycosylated Pls is only produced when SdgA/SdgB are present. (B) SDS-PAGE (7.5% separation gel) (upper panel) and corresponding PAS staining (lower panel) of surface proteins from S. aureus SH1000 (lane 2), SH1000 (pPLS4) (lane 3), SH1000sdgA/sdgB (lane 4) SH1000sdgA/sdgB (pPLS4) (lane 5), S. aureus Newman (lane 2), Newman (pPLS4) (lane 3), NewmansdgA/sdgB (lane 4) NewmansdgA/sdgB (pPLS4) (lane 5), S. aureus COL (lane 6), COLsdgA/sdgB (lane 7). Both, S. aureus COL and S. aureus COLsdgA/sdgB produce glycosylated Pls.
Fig 3The glycosyltransferases GtfC/GtfD mediate glycosylation of Pls.
(A) Schematic model of the 9.8 kbp and 10 kbp DNA fragment expressing pls, gtfC, and gtfD and the corresponding gene products Pls, GtfC, and GtfD from strain COL and strain 1061, respectively. The gtfC and gtfD genes are located downstream of pls and convergently transcribed. Putative promotors are indicated by arrows. SD; SD-repeat region, G5; G5 domains (Pfam accession number: PF077501), LPXTG; C-terminal cell-wall anchor motif. (B, C) SDS-PAGE (10% separation gel) (upper panels) and corresponding PAS staining (lower panels) of surface proteins from S. carnosus TM300 (B) and S. aureus SA113sdgA/sdgB (C) strains expressing genes from strain COL. S. carnosus TM300 and S. aureus SA113sdgA/sdgB produce glycosylated versions of Pls when pls is coexpressed with gtfC/gtfD. The lanes contain: (B) 2; S. carnosus (pCU1), 3; S. carnosus (pPlsGtfCDCOL), 4; S. carnosus (pPlsGtfΔCDCOL), 5; S. carnosus (pPlsGtfCΔDCOL), 6; S. carnosus (pPlsGtfΔCΔDCOL). (C) 2; S. aureus SA113sdgA/sdgB (pCU1), 3; S. aureus SA113sdgA/sdgB (pPlsGtfCDCOL), 4; S. aureus SA113sdgA/sdgB (pPlsGtfΔCDCOL), 5; S. aureus SA113sdgA/sdgB (pPlsGtfCΔDCOL), 6; S. aureus SA113sdgA/sdgB (pPlsGtfΔCΔDCOL). The sizes of the marker proteins (1; kDa) are indicated on the left. (D, E) SDS-PAGE (10% separation gel) (upper panels) and corresponding PAS staining (lower panels) of surface proteins from S. carnosus TM300 (D) and S. aureus SA113sdgA/sdgB (E) strains expressing genes from strain 1061. S. carnosus TM300 and S. aureus SA113sdgA/sdgB produce glycosylated versions of Pls when pls is coexpressed with gtfC/gtfD. The lanes contained: (D) 2; S. carnosus (pCU1), 3; S. carnosus (pPlsGtfCD1061), 4; S. carnosus (pPlsGtfΔCD1061), 5; S. carnosus (pPlsGtfCΔD1061), 6; S. carnosus (pPlsGtfΔCΔD1061). (E) 2; S. aureus SA113sdgA/sdgB (pCU1), 3; S. aureus SA113sdgA/sdgB (pPlsGtfCD1061), 4; S. aureus SA113sdgA/sdgB (pPlsGtfΔCD1061), 5; S. aureus SA113sdgA/sdgB (pPlsGtfCΔD1061), 6; S. aureus SA113sdgA/sdgB (pPlsGtfΔCΔD1061). The sizes of the marker proteins (1; kDa) are indicated on the left.
Fig 4Purification of Pls by using ConA.
(A) SDS-PAGE (7.5% separation gel) of surface proteins from S. aureus 1061 (I) and COL (II) and different fractions collected from a column packed with ConA sepharose. The lanes contained: 2; lysate fraction, 3; flow-through fraction, 4; wash fraction, 5; eluted fraction. The sizes of the marker proteins (lane 1; kDa) are indicated on the left. (B-E) Purification of Pls produced by S. carnosus TM300 (B, D) or by S. aureus SA113sdgA/sdgB (C, E) by using ConA. (B, C) SDS-PAGE (7.5% separation gel) (upper panel) and corresponding PAS staining (lower panel) and (D, E) SDS-PAGE (7.5% separation gel) of surface proteins (lanes 2, 4, 6) and eluted fractions (lanes 3, 5, 7) collected from a column packed with ConA sepharose. The lanes contained: (B) 2,3: S. carnosus (pPlsGtfCDCOL); 4,5: S. carnosus (pPlsGtfΔCDCOL); 6,7; S. carnosus (pPlsGtfCΔDCOL). (D) 2,3: S. carnosus (pPlsGtfCD1061); 4,5: S. carnosus (pPlsGtfΔCD1061); 6,7; S. carnosus (pPlsGtfCΔD1061). (C) 2,3: S. aureus SA113sdgA/sdgB (pPlsGtfCDCOL); 4,5: S. aureus SA113sdgA/sdgB (pPlsGtfΔCDCOL); 6,7: S. aureus SA113sdgA/sdgB (pPlsGtfCΔDCOL). (E) 2,3: S. aureus SA113sdgA/sdgB (pPlsGtfCD1061); 4,5: S. aureus SA113sdgA/sdgB (pPlsGtfΔCD1061); 6,7: S. aureus SA113sdgA/sdgB (pPlsGtfCΔD1061). The sizes of the marker proteins (lane 1; kDa) are indicated on the left.
Fig 6Determination of the modifying carbohydrate moieties.
(A) NanoESI Q-Tof mass spectrum of a hydrolysate obtained from a Pls preparation derived from S. aureus strain 1061 by incubation with 12.5% (v/v) acetic acid for 2 h at 95°C. For reasons of clarity only a few signals originating from (glyco)peptides derived from the SD repeats are labeled. A summary of all detected corresponding species is given in S1 Table. (B) NanoESI Q-Tof fragment ion spectrum obtained from a CID experiment on the singly charged precursor glycopeptide ions with m/z 626.25. The insert shows the corresponding fragmentation scheme.
Ratios of relative intensities of signals derived from glycosylated and non-glycosylated SD-repeat hydrolytic peptides obtained from Pls preparations of S. aureus strain COL and its sdgA/sdgB mutant.
| Peptide | SD | SD-HexNAc | SDAD | SDAD- HexNAc | SDSD | SDSD- HexNAc | SDSD- HexNAc2 |
|---|---|---|---|---|---|---|---|
| Sample | |||||||
| Pls_COL | 221.08 | 424.16 | 407.17 | 610.23 | 423.14 | 626.25 | 829.30 |
| Pls_COL | 221.08 | 424.17 | 407.16 | 610.23 | 423.15 | 626.27 | 829.31 |
Fig 7Functional characterization of Pls glycosylation.
(A) Pls reduces the adherence of S. aureus to Fg, Fn, and endothelial cells independently of its glycosylation status. The wells of microtiter plates were coated with Fg, Fn or endothelial cells, blocked, and incubated with the bacteria. After washing, binding was assessed as arbitrary units in ELISA adherence assays. Results are shown as the mean of three independent experiments. Statistical significance is marked by asterisks. (B) Pls reduces the internalization of S. aureus by endothelial EA.hy 926 cells independently of its glycosylation status. The internalization of FITC-labeled S. aureus strains by adherent EA.hy 926 cells was assessed by flow cytometry and computed in relation to S. aureus strain Cowan 1, which was set to 100% internalization. Data are shown as the mean of three independent experiments. Statistical significance is marked by asterisks. (C, D) Pls reduces the phagocytosis of S. aureus by PMNs independently of its glycosylation status. The phagocytosis of FITC-labelled S. aureus strains by PMNs was assessed by flow cytometry and computed in relation to S. aureus SA113 (pCU1), which was set to 100%. Data are shown as the mean of three independent experiments. Statistical significance is marked by asterisks.
Fig 8Expression of glycosylated Pls increases biofilm formation of S. aureus Newman.
(A) Quantitative assay of biofilm formation. Strains were grown in TSB in microtiter plates. S. epidermidis RP62A and S. carnosus TM300 served as positive and negative controls, respectively. Data are shown as the mean of four independent experiments. Statistical significance is marked by asterisks. (B) Initial attachment to a plastic surface. Attached bacterial cells were analysed by phase-contrast microscopy, photographed and counted. Each assay was performed in triplicates. Data are shown as the mean of three independent experiments. (C) Biofilm formation on a glass surface. S. epidermidis RP62A and S. carnosus TM300 served as positive and negative controls, respectively. (D) Proteinase K (0.1 mg/ml) or (E) NaIO4 (40 mM) treatment (+) of preformed biofilms in microtiter plates and untreated controls (-). S. epidermidis RP62A served as a control. Data are shown as the mean of three independent experiments. Statistical significance is marked by asterisks. (F) Biofilm formation in the presence (+) or absence (-) of DNase I (0.1 mg/ml). S. epidermidis RP62A served as a control. Data are shown as the mean of three independent experiments. Statistical significance is marked by asterisks.
Primers used in this study.
| Primer name | Oligonucleotide sequence (5´→ 3´; restriction site underlined) |
|---|---|
| TE-P1-PstI1 | AA |
| TE-P3-HindIII1 | CCC |
| TE-P1-XbaI1 | GAGTTATACAAC |
| TE-P4-EcoRI1 | GGACATATCTTA |
| Rmgts41 | TATAT |
| Rmgts51 | TTATA |
| Rmgts61 | TTTAA |
| Rmgts71 | TATTA |
| Fkan11 | GGCGG |
| Rkan21 | GGGGC |
| PlsGtfCD-F1 | ATAT |
| PlsGtfCD-R1 | ATAT |
| Pls4Sub1-R1 | GTCTGCATCAGAATCGCTATCTGCGTCTGAATCGCTGTCCGC |
| Pls4Sub2-R1 | GCTGTCTGAATCGCTGTCCGCATCAGAGTCGCTATCTGCGTC |
| Pls4Sub3-R1 | TGCGTCTGAGTCGCTGTCTGCATCAGAATCGCTATCTGC |
| Pls4Sub1/2/3-F1 | AGAGATCATAATGACAAAACAGATAAACCAAATAATAAAGAG |
| GtfC-F2 | GTAGTACTAATTTCTTACAAAATATG |
| GtfC-R2 | CAATAAGTGAGTTGTCTCATATG |
| GtfD-F2 | CAGGAGAATAACGTGCAACGG |
| GtfD-R2 | GATCTATATGATTCAAGAGGCT |
| GtfC-mutF2 | TGGCAGACGTCGTAAAAACA |
| GtfC-mutR2 | TCAAGCACTCTAAAGCTTTTTCAA |
| GtfD-mutF2 | AAAAACCCATCAAGAATACTAGGAA |
| GtfD-mutR2 | GAACGACAAAACTTCACTGTTGA |
| Pls6B-F2 | CGCGGATCCTACCAATGAATATGGTTGTTACAAATAG |
| Pls6K-F-15812 | TATGGTACCGCAGATAGAGATCATAATGACAAAACAGATAAACC |
| Pls6B-R-16372 | ATAGGATCCTTATTTTTCTTCATTATTTTTGTTTTTACGACGTCTGCC |
| Sub-SD-R2 | ATCATCTTTAGCACCATGGATGATTACTTCATC |
| Pls-F2 | GGTAATGTTCAAACTATTGAAC |
| Stop-Pls-R2 | TTATTTTTCTTCATTATTTTTGTTTTTA |
| SdgAB-B-F2 | ATATGGATCCAACGGCTCAAATAACGCAACG |
| SdgAB-X-R2 | ATATCCCGGGATCGACACGAGAAGGTCGTT |
| SdgA-F22 | TCGTCCTCATGAATTAGGAAATG |
| SdgB-R22 | AACGTCCTGATGAAAAACGTG |
| 1061-SdgB-F2 | CAAATTGGTCCCATTGTTTAAT |
| 1061-IS | TGAACGATATGGAATCTGTCAAA |
| SaeS-F2 | CCGTATTAGAGAAAAATTAGAAAAAGAGAGC |
| SaeS-R2 | CAAAAAAAGAAGCCCTCATTAATGGG |
| SaeR-F2 | GAGTCACTCATTGTTAAAACAGATTTCAC |
| SaeR-R2 | ATGCAATTGCTAAAATAGTTGAAGTTAATGG |
Primers used for 1cloning and 2sequencing.